{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T23:09:07Z","timestamp":1768345747869,"version":"3.49.0"},"reference-count":17,"publisher":"American Society of Hematology","issue":"7","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2004,4,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Chronic transfusion of packed red blood cells, in addition to other ongoing treatment with warfarin, acetyl salicylic acid, desferrioxamine, and other supportive measures, was given to a splenectomized hemoglobin E\/\u03b2-thalassemia woman with pulmonary arterial hypertension (PHT). Serial measurements of plasma thrombin-antithrombin III complex (TAT) levels and right-sided cardiac catheterization were used to monitor changes after treatment. Reduction of plasma TAT levels from 7.5 to 3.8 \u03bcg\/L (normal, 3 \u00b1 2.4 \u03bcg\/L), pulmonary vascular resistance (PVR) from 553.8 to 238.6 dyne.sec.cm-5 (normal, 67 \u00b1 30 dyne.sec.cm-5), and mean pulmonary arterial pressure from 51 to 32 mm Hg (normal, 9 to 19 mm Hg) occurred in tandem. Normalization of blood hypercoagulability as reflected in plasma TAT level by chronic blood transfusion was the likely basis for improvement of increased PVR, being secondary to thrombotic pulmonary arteriopathy and subsequently PHT. (Blood. 2004;103: 2844-2846)<\/jats:p>","DOI":"10.1182\/blood-2003-09-3094","type":"journal-article","created":{"date-parts":[[2003,12,2]],"date-time":"2003-12-02T01:14:00Z","timestamp":1070327640000},"page":"2844-2846","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":62,"title":["Correction of hypercoagulability and amelioration of pulmonary arterial hypertension by chronic blood transfusion in an asplenic hemoglobin E\/\u03b2-thalassemia patient"],"prefix":"10.1182","volume":"103","author":[{"given":"Vichai","family":"Atichartakarn","sequence":"first","affiliation":[{"name":"From the Divisions of Hematology and Cardiology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suporn","family":"Chuncharunee","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Cardiology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pakorn","family":"Chandanamattha","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Cardiology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khanchit","family":"Likittanasombat","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Cardiology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katcharin","family":"Aryurachai","sequence":"additional","affiliation":[{"name":"From the Divisions of Hematology and Cardiology, Department of Medicine, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2020021218390769900_REF1","unstructured":"Rich S. Pulmonary hypertension. In: Braunwald E, Zipes DP, Libby P, eds. Heart Disease. A Textbook of Cardiovascular Medicine. Philadelphia, PA: WB Saunders; 2001: 1908-1935."},{"key":"2020021218390769900_REF2","unstructured":"Gibbs JSR, Higenbottam TW. Recommendations on the management of pulmonary hypertension in clinical practice. Heart. 2001;86(suppl 1): i1-i13."},{"key":"2020021218390769900_REF3","doi-asserted-by":"crossref","unstructured":"Aessopos A, Farmakis D, Karagiorga M, et al. Cardiac involvement in thalassemia intermedia: a multicenter study. Blood. 2001;97: 3411-3416.","DOI":"10.1182\/blood.V97.11.3411"},{"key":"2020021218390769900_REF4","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Likittanasombat K, Chuncharunee S, et al. Pulmonary arterial hypertension in previously splenectomized patients with \u03b2-thalassemic disorders. Int J Hematol. 2003;78: 139-145.","DOI":"10.1007\/BF02983382"},{"key":"2020021218390769900_REF5","doi-asserted-by":"crossref","unstructured":"Adedeji MO, Cespedes J, Allen K, et al. Pulmonary thrombotic arteriopathy in patients with sickle cell disease. Arch Pathol Lab Med. 2001;125: 1436-1441.","DOI":"10.5858\/2001-125-1436-PTAIPW"},{"key":"2020021218390769900_REF6","unstructured":"Fucharoen S, Yongchaiyud P, Wasi P. Hypoxaemia and the effect of aspirin in thalassaemia. Southeast Asian J Trop Med Public Health. 1981;12: 90-93."},{"key":"2020021218390769900_REF7","doi-asserted-by":"crossref","unstructured":"Eldor A, Rachmilewitz EA. The hypercoagulable state in thalassemia. Blood. 2002;99: 36-43.","DOI":"10.1182\/blood.V99.1.36"},{"key":"2020021218390769900_REF8","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. Relationship between hypercoagulable state and erythrocyte phosphatidylserine exposure in splenectomized haemoglobin E\/\u03b2-thalassaemic patients. Br J Haematol. 2002;118: 893-898.","DOI":"10.1046\/j.1365-2141.2002.03711.x"},{"key":"2020021218390769900_REF9","doi-asserted-by":"crossref","unstructured":"Eldor A, Lellouche F, Goldfarb A, et al. In vivo platelet activation in beta thalassemia major reflected by increased platelet thromboxane urinary metabolites. Blood. 1991;77: 1749-1753.","DOI":"10.1182\/blood.V77.8.1749.1749"},{"key":"2020021218390769900_REF10","doi-asserted-by":"crossref","unstructured":"Del-Principe D, Menichelli A, Di Giulio S, et al. PADGEM\/GMP-140 expression on platelet membrane from homozygous \u03b2-thalassaemia patients. Br J Haematol. 1993;84: 111-117.","DOI":"10.1111\/j.1365-2141.1993.tb03033.x"},{"key":"2020021218390769900_REF11","doi-asserted-by":"crossref","unstructured":"Ruf A, Pick M, Deutsch V, et al. In-vivo platelet activation correlates with red cell anionic phospholipid exposure in patients with \u03b2-thalassaemia major. Br J Haematol. 1997;98: 51-56.","DOI":"10.1046\/j.1365-2141.1997.1502965.x"},{"key":"2020021218390769900_REF12","doi-asserted-by":"crossref","unstructured":"Atichartakarn V, Angchaisuksiri P, Aryurachai K, et al. In vivo platelet activation and hyperaggregation in hemoglobin E\/\u03b2-thalassemia: a consequence of splenectomy. Int J Hematol. 2003;77: 299-303.","DOI":"10.1007\/BF02983790"},{"key":"2020021218390769900_REF13","doi-asserted-by":"crossref","unstructured":"Closse C, Dachary-Prigent J, Boisseau MR. Phosphatidylserine-related adhesion of human erythrocytes to vascular endothelium. Br J Haematol. 1999;107: 300-302.","DOI":"10.1046\/j.1365-2141.1999.01718.x"},{"key":"2020021218390769900_REF14","doi-asserted-by":"crossref","unstructured":"Pietra GG, Edwards WD, Kay JM, et al. Histopathology of primary pulmonary hypertension. Circulation. 1989;80: 1198-1206.","DOI":"10.1161\/01.CIR.80.5.1198"},{"key":"2020021218390769900_REF15","doi-asserted-by":"crossref","unstructured":"Pasin M, Yavuzer S, Tekin M, et al. Oxygen free radical dependent increased platelet function in \u03b2-thalassemia major patients. Thromb Res. 1998;92: 283-286.","DOI":"10.1016\/S0049-3848(98)00129-7"},{"key":"2020021218390769900_REF16","unstructured":"Claster S, Hammer M, Hagar W, et al. Treatment of pulmonary hypertension in sickle cell disease with transfusion [abstract]. Blood. 1999;94: 420a."},{"key":"2020021218390769900_REF17","doi-asserted-by":"crossref","unstructured":"Wandersee NJ, Lee JC, Deveau SA, et al. Reduced incidence of thrombosis in mice with hereditary spherocytosis following neonatal treatment with normal hematopoietic cells. Blood. 2001;97: 3972-3975.","DOI":"10.1182\/blood.V97.12.3972"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/7\/2844\/1697164\/zh800704002844.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/103\/7\/2844\/1697164\/zh800704002844.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,13]],"date-time":"2021-06-13T08:23:44Z","timestamp":1623572624000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/103\/7\/2844\/18261\/Correction-of-hypercoagulability-and-amelioration"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4,1]]},"references-count":17,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2004,4,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2003-09-3094","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4,1]]}}}